Purpose: To report the case of a patient with a diagnosis of infiltrative ductal carcinoma of the breast (case 1) and of a patient with Hodgkin's lymphoma (case 2), both submitted to ovarian stimulation during the luteal phase of the menstrual cycle in order to cryopreserve embryos and oocytes, respectively, in view of the need to start chemotherapy within a maximum of three weeks.
Methods: Case reports.
Results: Both patients were submitted to ovarian stimulation with recombinant follicle stimulating hormone together with pituitary blockade with a GnRH antagonist during the luteal phase of the cycle. Oocyte retrieval was performed nine days after the beginning of ovarian stimulation, with 12 mature oocytes being obtained in both cases. In case 1, all mature oocytes were submitted to ICSI, with fertilization and cleavage rates of 83.3% and 70%, respectively, and with the formation of seven good quality embryos. In case 2, all of mature oocytes were cryopreserved.
Conclusions: These cases demonstrate that it is possible to obtain mature oocytes when ovarian stimulation is started in the luteal phase in situations in which there is not sufficient time for conventional stimulation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941583 | PMC |
| http://dx.doi.org/10.1007/s10815-010-9429-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Safety and effectiveness of controlled ovarian stimulation and oocyte retrieval during prepubertal and peripubertal period.
J Assist Reprod Genet
January 2025
Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, 06620, Turkey.
Birth defects reporting and the use of dydrogesterone: a disproportionality analysis from the World Health Organization pharmacovigilance database (VigiBase).
Hum Reprod Open
January 2025
Regional Center of Pharmacovigilance, Pharmacology Department, Cochin Hospital, AP-HP.Centre-Université Paris Cité, Paris, France.
Study Question: Is there an association between dydrogesterone exposure during early pregnancy and the reporting of birth defects?
Summary Answer: This observational analysis based on global safety data showed an increased reporting of birth defects, mainly hypospadias and congenital heart defects (CHD), in pregnancies exposed to dydrogesterone, especially when comparing to progesterone.
What Is Known Already: Intravaginal administration of progesterone is the standard of care to overcome luteal phase progesterone deficiency induced by ovarian stimulation in ART. In recent years, randomized controlled clinical trials demonstrated that oral dydrogesterone was non-inferior for pregnancy rate at 12 weeks of gestation and could be an alternative to micronized vaginal progesterone.
Predicting factors of ovarian responses in infertile women with polycystic ovary syndrome undergoing IVF/ICSI.
J Assist Reprod Genet
January 2025
Department of Assisted Reproductive Medicine, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, 2699nd West Gao Ke Road, Shanghai, 201204, China.
Purpose: Women with polycystic ovary syndrome (PCOS) show greater heterogeneity in ovarian responses during ovarian stimulation. We aimed to investigate the potential predicting factors among individualized basic parameters that affect poor or hyper ovarian responses in PCOS patients.
Methods: We retrospectively screened 2058 women with PCOS who underwent their first cycle of in vitro fertilization/intracytoplasmic sperm injection.
Objective: We aimed to compare highly purified human menopausal gonadotropin (hp-hMG) and recombinant follicle stimulating hormone (rFSH) in short antagonist in vitro fertilization (IVF) cycles of patients with poor ovarian reserve (POR). Limited research exists on this comparison in short antagonist cycles for this patient group.
Materials And Methods: This retrospective cohort study involved 165 POR patients aged 18-45 years who underwent IVF between 2018 and 2022.
Chemotherapy-induced diminished murine ovarian reserve model and impact of low-dose chemotherapy on fertility.
F S Sci
January 2025
Gynecology Research Unit, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; Gynecology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium. Electronic address:
Objective: To establish a murine model of chemotherapy-induced diminished ovarian reserve (DOR) and investigate residual fertility after chemotherapy exposure.
Design: Two different chemotherapy protocols were tested to establish a valid DOR model by comparing follicle densities in mice given either protocol versus physiological solution. An ovarian stimulation protocol was then selected from among different gonadotropins by counting the number of day-2 embryos obtained from normal mice.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!